1
|
Kuemper M, Hessenthaler S, Zamek J, Mauch C, Zigrino P. 434 Deletion of endothelial cell MMP14 reduces melanoma growth and skin fibrosis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Schlaak M, Dummer R, Kirkwood J, Joshua A, Milhem M, Gastaud L, Mauch C, Yushak M, Lockwood S, Hayes C, Shoushtari A. 821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
3
|
Pflug N, Vitus M, Knuever J, Hamacher S, Mauch C, Schlaak M, Theurich S. Treatment‐specific evaluation of the modified Glasgow‐Prognostic‐Score in patients with advanced cutaneous melanoma. J Eur Acad Dermatol Venereol 2021. [DOI: 10.1111/jdv.17533 epub 2021 aug 4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- N. Pflug
- Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf University Hospital Cologne University of Cologne Cologne Germany
| | - M. Vitus
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf University Hospital Cologne University of Cologne Cologne Germany
- Department of Dermatology and Allergology Biederstein School of Medicine Technical University Munich Germany
| | - J. Knuever
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf University Hospital Cologne University of Cologne Cologne Germany
| | - S. Hamacher
- Faculty of Medicine and University Hospital Cologne Institute of Medical Statistics and Computational Biology University of Cologne Cologne Germany
| | - C. Mauch
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf University Hospital Cologne University of Cologne Cologne Germany
| | - M. Schlaak
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf University Hospital Cologne University of Cologne Cologne Germany
- Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany
| | - S. Theurich
- Cancer and Immunometabolism Research Group Gene Center LMU Munich Munich Germany
- Department of Medicine III LMU University Hospital Munich Germany
- German Cancer Consortium (DKTK) Partner site Munich, Germany, and German Cancer Research Center (DKFZ) Heidelberg Germany
| |
Collapse
|
4
|
Pach E, Brinckmann J, Rübsam M, Kümper M, Mauch C, Zigrino P. 274 Role of fibroblast-MMP14 in melanoma growth. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Kümper M, Hessenthaler S, Zamek J, Niland S, Pach E, Mauch C, Zigrino P. 252 Loss of endothelial cell MMP14 reduces melanoma growth and metastasis by increasing tumor vessel stability. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Meissner A, Gutsche R, Galldiks N, Kocher M, Juenger ST, Wendl C, Mauch C, Proescholdt M, Grau S, Lohmann P. P14.06 Radiomics for the non-invasive determination of the BRAF mutational status in patients with melanoma brain metastases. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
The BRAF V600E mutation is present in approximately 50% of patients with melanoma and is an important prerequisite for a response to targeted therapies such as BRAF inhibitors. In the majority of patients, the BRAF mutational status is based on the analysis of tissue samples from the extracranial primary tumor only. Since the extracranial and intracranial BRAF mutational status may be discrepant, the additional information on the BRAF mutational status of melanoma brain metastases would be of clinical value, e.g., for the prediction of response to targeted therapies. Here, we evaluated the potential of structural MRI radiomics for the determination of the intracranial BRAF mutational status in patients with melanoma brain metastases.
MATERIAL AND METHODS
Fifty-nine patients with melanoma brain metastases from two university hospitals (group 1, 45 patients; group 2, 14 patients) underwent surgery with subsequent genetic analysis of the brain metastases tissue to determine the BRAF mutational status. All patients underwent structural MRI preoperatively. Areas of contrast enhancement were manually segmented and analyzed. Group 1 was used for model training and validation, group 2 for model testing. After image preprocessing, 1,316 radiomics features were extracted using the open-source PyRadiomics package. A test-retest analysis was performed to identify robust features prior to feature selection. Finally, the best performing radiomics model was applied to the test data (group 2). Diagnostic performances were evaluated using receiver operating characteristic (ROC) analyses.
RESULTS
Twenty-two patients (49%) in group 1, and 6 patients (43%) in group 2 had an intrametastatic BRAF V600E mutation. Using a six parameter radiomics signature, a linear support vector machine classifier yielded an average area under the ROC curve (AUC) of 0.87 (accuracy, 85%; sensitivity, 78%; specificity, 91%) for prediction of the BRAF mutational status in the training data (group 1). Finally, the classifier achieved an AUC of 0.85 (accuracy, 86%; sensitivity, 83%; specificity, 88%) in the test data (group 2).
CONCLUSION
The developed radiomics classifier allows a non-invasive prediction of the intracranial BRAF V600E mutational status in patients with melanoma brain metastases and may be of value for treatment decisions.
Collapse
Affiliation(s)
- A Meissner
- Dept. of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - R Gutsche
- Inst. of Neuroscience and Medicine (INM-4), Research Center Juelich, Juelich, Germany
| | - N Galldiks
- Inst. of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany
- Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - M Kocher
- Inst. of Neuroscience and Medicine (INM-4), Research Center Juelich, Juelich, Germany
- Dept. of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - S T Juenger
- Dept. of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - C Wendl
- Dept. of Radiology and Division of Neuroradiology, University Hospital Regensburg, Regensburg, Germany
| | - C Mauch
- Dept. of Dermatology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - M Proescholdt
- Dept. of Neurosurgery, University Hospital Regensburg, Regensburg, Germany
- Wilhelm Sander Neuro-Oncology Unit, University Hospital Regensburg, Regensburg, Germany
| | - S Grau
- Dept. of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - P Lohmann
- Inst. of Neuroscience and Medicine (INM-4), Research Center Juelich, Juelich, Germany
- Dept. of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| |
Collapse
|
7
|
Pflug N, Vitus M, Knuever J, Hamacher S, Mauch C, Schlaak M, Theurich S. Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma. J Eur Acad Dermatol Venereol 2021; 35:e879-e883. [PMID: 34310762 DOI: 10.1111/jdv.17533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 07/21/2021] [Indexed: 11/30/2022]
Affiliation(s)
- N Pflug
- Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - M Vitus
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.,Department of Dermatology and Allergology, Biederstein, School of Medicine, Technical University, Munich, Germany
| | - J Knuever
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - S Hamacher
- Faculty of Medicine and University Hospital Cologne, Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - C Mauch
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - M Schlaak
- Department of Dermatology and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.,Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany
| | - S Theurich
- Cancer and Immunometabolism Research Group, Gene Center, LMU Munich, Munich, Germany.,Department of Medicine III, LMU University Hospital, Munich, Germany.,German Cancer Consortium (DKTK), Partner site Munich, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
8
|
Grau S, Herling M, Mauch C, Galldiks N, Golla H, Schlamann M, Scheel AH, Celik E, Ruge M, Goldbrunner R. [Brain metastases-Interdisciplinary approach towards a personalized treatment]. Chirurg 2021; 92:200-209. [PMID: 33502584 DOI: 10.1007/s00104-020-01344-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/17/2020] [Indexed: 12/01/2022]
Abstract
The incidence, treatment and prognosis of patients with brain metastases have substantially changed during the last decades. While the survival time after diagnosis of cerebral metastases was on average a maximum of 3-6 months only 10 years ago, the survival time could be significantly improved due to novel surgical, radiotherapeutic and systemic treatment modalities. Only a few years ago, the occurrence of brain metastases led to a withdrawal from systemic oncological treatment and the exclusion of drug therapy studies and to a purely palliatively oriented treatment in the sense of whole brain radiation therapy (WBRT) with or without surgery. The increasing availability of targeted and immunomodulatory drugs as well as adapted radio-oncological procedures enable increasingly more personalized treatment approaches. The aim of this review article is to demonstrate the progress and complexity of the treatment of brain metastases in the context of modern comprehensive interdisciplinary concepts.
Collapse
Affiliation(s)
- S Grau
- Klinik für Allgemeine Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Kerpener Str. 62, 50937, Köln, Deutschland. .,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.
| | - M Herling
- Klinik I für Innere Medizin, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - C Mauch
- Klinik für Dermatologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - N Galldiks
- Klinik für Neurologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Institut für Neurowissenschaften und Medizin (INM-3), Forschungszentrum Jülich, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - H Golla
- Zentrumfür Palliativmedizin, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - M Schlamann
- Institut für Radiologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - A H Scheel
- Institut für Pathologie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - E Celik
- Klinik für Radioonkologie, Cyberknife und Strahlentherapie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - M Ruge
- Klinik für Stereotaxie und funktionelle Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| | - R Goldbrunner
- Klinik für Allgemeine Neurochirurgie, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Kerpener Str. 62, 50937, Köln, Deutschland.,Centrum für Integrierte Onkologie (CIO) Aachen Bonn Köln Düsseldorf, Universität zu Köln, Medizinische Fakultät, Klinikum der Universität, Köln, Deutschland
| |
Collapse
|
9
|
Fromme J, Mauch C, Zigrino P. 515 Potential mediators of melanoma cell resistance. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Pach E, Brinckmann J, Fox J, Mauch C, Zigrino P. 449 Deletion of fibroblast MMP-14 in the skin leads to reduced melanoma growth. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Persa OD, Loquai C, Wobser M, Baltaci M, Dengler S, Kreuter A, Volz A, Laimer M, Emberger M, Doerler M, Mauch C, Helbig D. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. J Eur Acad Dermatol Venereol 2019; 33:1577-1580. [PMID: 30767327 DOI: 10.1111/jdv.15493] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 01/18/2019] [Indexed: 12/01/2022]
Abstract
BACKGROUND Pleomorphic dermal sarcomas (PDS) are frequent UV-induced sarcomas of the skin of intermediate grade malignant potential. Despite the fact that PDS have a noteworthy potential to recur (up to 28%) as well as to metastasize (up to 20%), there are no specific clinical guidelines with respect to follow-up these patients. Moreover, little is known about clinical, histological or molecular prognostic factors in PDS. OBJECTIVE The aim of the present study was to identify risk factors to predict relapse in a large multicentre sample cohort of PDS which could aid to optimize personalized treatment recommendations regarding surgical safety margins and adjuvant radiotherapy. METHODS Patients with a diagnosis of PDS were selected from nine European institutions based on the histopathologic criteria described by Fletcher. Clinicopathologic and follow-up data were collected and statistically analysed calculating univariate hazard ratios with 95% confidence intervals by use of the Cox proportional-hazards model and a significance level of P < 0.05. Patients with an incomplete excision of the tumour were excluded. RESULTS Univariate Cox regression analysis of possible prognostic factors for progression-free survival (PFS) performed in 92 patients revealed that an excision margin of <2 cm is significantly associated with relapse of PDS [hazard ratio 4.478 (95% CI 1.536-13.055), P = 0.006]. Ulceration of the tumour was associated with a significantly better prognosis [0.396 (0.174-0.904), P = 0.028] whereas adjuvant radiotherapy did not reach statistical significance to improve prognosis in patients with PDS [0.775 (0.231-2.593), P = 0.679]. Gender, age, immunosuppression, intratumoural necrosis, tumour location, vertical thickness or horizontal diameter did not significantly influence PFS in PDS. CONCLUSION We identified surgical safety margins of <2 cm and absence of ulceration as risk factors for relapse in patients with PDS. These findings may be implemented into both the primary treatment as well as the further monitoring of patients with PDS.
Collapse
Affiliation(s)
- O D Persa
- Department of Dermatology and Venereology, University of Cologne, Cologne, Germany
| | - C Loquai
- Department of Dermatology, University Medical Center Mainz, Mainz, Germany
| | - M Wobser
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - M Baltaci
- Department of Dermatology, Helios Hospital Krefeld, Krefeld, Germany
| | - S Dengler
- Department of Dermatology, Dortmund Hospital, Dortmund, Germany
| | - A Kreuter
- Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Oberhausen, Germany
| | - A Volz
- Department of Dermatology, University Hospital Basel, Basel, Switzerland
| | - M Laimer
- Department of Dermatology, University Hospital Salzburg, Paracelsus Private Medical University of Salzburg, Salzburg, Austria
| | - M Emberger
- Institute of Pathology, Salzburg, Austria
| | - M Doerler
- Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany
| | - C Mauch
- Department of Dermatology and Venereology, University of Cologne, Cologne, Germany
| | - D Helbig
- Department of Dermatology and Venereology, University of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol 2019; 30:317-324. [PMID: 30428063 PMCID: PMC6386028 DOI: 10.1093/annonc/mdy500] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors trametinib or pazopanib to paclitaxel chemotherapy improved outcomes in patients with advanced BRAF-wt melanoma in a phase II, randomised and open-label trial. PATIENTS AND METHODS Patients were randomised (1 : 1 : 1) to paclitaxel alone or with trametinib or pazopanib. Paclitaxel was given for a maximum of six cycles, while 2 mg trametinib and 800 mg pazopanib were administered orally once daily until disease progression or unacceptable toxicity. Participants and investigators were unblinded. The primary end point was progression-free survival (PFS). Key secondary end points included overall survival (OS) and objective response rate (ORR). RESULTS Participants were randomised to paclitaxel alone (n = 38), paclitaxel and trametinib (n = 36), or paclitaxel and pazopanib (n = 37). Adding trametinib significantly improved 6-month PFS [time ratio (TR), 1.47; 90% confidence interval (CI) 1.08-2.01, P = 0.04] and ORR (42% versus 13%; P = 0.01) but had no effect on OS (P = 0.25). Adding pazopanib did not benefit 6-month PFS; (TR 1.36; 90% CI 0.96-1.93; P = 0.14), ORR, or OS. Toxicity increased in both combination arms. CONCLUSION In this phase II trial, adding trametinib to paclitaxel chemotherapy for BRAF-wt melanoma improved PFS and substantially increased ORR but did not impact OS.This study was registered with the EU Clinical Trials Register, EudraCT number 2011-002545-35, and with the ISRCTN registry, number 43327231.
Collapse
Affiliation(s)
- V Urbonas
- Early Phase Clinical Trials Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; National Cancer Institute, Vilnius, Lithuania
| | - D Schadendorf
- Department of Dermatology, University Hospital Essen, West German Cancer Centre, University Duisburg-Essen, Essen, Germany; The German Cancer Consortium, Essen, Germany
| | - L Zimmer
- Department of Dermatology, University Hospital Essen, West German Cancer Centre, University Duisburg-Essen, Essen, Germany; The German Cancer Consortium, Essen, Germany
| | - S Danson
- Department of Oncology, Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, UK
| | - E Marshall
- Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK
| | - P Corrie
- Department of Oncology, Addenbrookes Hospital, Cambridge, UK
| | - M Wheater
- Department of Oncology, Southampton General Hospital, Southampton, UK
| | - E Plummer
- Department of Oncology, Freeman Hospital, Newcastle upon Tyne, UK
| | - C Mauch
- Köln Universitätsklinik, Köln, Germany
| | - C Scudder
- Oncology Clinical Trials Office, University of Oxford, Oxford, UK
| | - M Goff
- Oncology Clinical Trials Office, University of Oxford, Oxford, UK
| | - S B Love
- Centre for Statistics in Medicine, University of Oxford, Oxford, UK
| | - S B Mohammed
- Centre for Statistics in Medicine, University of Oxford, Oxford, UK
| | - M R Middleton
- Early Phase Clinical Trials Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Oncology, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
| |
Collapse
|
13
|
Giebeler N, Schönefuß A, Landsberg J, Tueting T, Mauch C, Zigrino P. 525 ADAM9 modulates melanoma development and metastasis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Hoerster R, Schlaak M, Koch KR, Ortmann M, Mauch C, Heindl LM. Merkel-Zell-Karzinom des Augenlids – eine häufig verkannte Diagnose. Ophthalmologe 2016; 114:134-139. [DOI: 10.1007/s00347-016-0355-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Zigrino P, Brinckmann J, Niehoff A, Lu Y, Giebeler N, Eckes B, Kadler K, Mauch C. 573 Fibroblast derived MMP-14 is the main collagenase for skin homeostasis. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Mescher M, Jeong P, Rübsam M, Kranen M, Landsberg J, Schlaak M, Mauch C, Tueting T, Niessen C, Iden S. 492 Non-cell autonomous suppression of melanoma by the epidermal polarity protein Par3 through control of direct keratinocyte-melanocyte interactions. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Heuser S, Hufbauer M, Steiger J, Marshall J, Sterner-Kock A, Mauch C, Zigrino P, Akgül B. The fibronectin/α3β1 integrin axis serves as molecular basis for keratinocyte invasion induced by βHPV. Oncogene 2016; 35:4529-39. [PMID: 26804167 DOI: 10.1038/onc.2015.512] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 12/09/2015] [Accepted: 12/11/2015] [Indexed: 12/18/2022]
Abstract
Organ-transplant-recipients exhibit cancerization of the skin from which multiple human papillomavirus (HPV)-positive squamous cell carcinomas (SCCs) arise. However, the molecular basis for HPV-induced invasion of skin keratinocytes is not known. We generated a transgenic mouse model expressing the E7 oncoprotein of HPV8 in the murine epidermis under the control of the keratin-14 promoter and showed that E7 is carcinogenic in mice. We further showed that both, the E7-expressing keratinocyte and mesenchymal components of the extracellular matrix as critical in eliciting the invasive behavior. E7 expression in basal keratinocytes, grown on fibronectin, led to epithelial-mesenchymal transition mediated by a cadherin switch. E7-positive keratinocytes displayed enhanced EDA-fibronectin expression and secretion and stimulated dermal fibroblasts to express EDA-fibronectin. Deposition of fibronectin was also detected in the peritumoral stroma of HPV8-positive skin SCC. When grown on fibronectin, E7-positive keratinocytes, in particular stem cell-like cells, exhibited increased cell surface levels of the α3-integrin chain. Functional blocking confirmed α3 as a critical molecule sufficient to induce E7-mediated invasion. This mechanistic link is further supported by expression of an E7-mutant, impaired in targeting α3 to the cell surface. These findings highlight the importance of epithelial-extracellular matrix interaction required for keratinocyte invasion and provide further mechanistic evidence for a role of HPV in skin carcinogenesis.
Collapse
Affiliation(s)
- S Heuser
- Institute of Virology, University of Cologne, Cologne, Germany
| | - M Hufbauer
- Institute of Virology, University of Cologne, Cologne, Germany
| | - J Steiger
- Department of Dermatology and Venerology, University of Cologne, Cologne, Germany
| | - J Marshall
- Barts Cancer Institute, Centre for Tumour Biology, Queen Mary University of London, John Vane Science Centre, London, UK
| | - A Sterner-Kock
- Center for Experimental Medicine, University Hospital, University of Cologne, Cologne, Germany
| | - C Mauch
- Department of Dermatology and Venerology, University of Cologne, Cologne, Germany
| | - P Zigrino
- Department of Dermatology and Venerology, University of Cologne, Cologne, Germany
| | - B Akgül
- Institute of Virology, University of Cologne, Cologne, Germany
| |
Collapse
|
18
|
Batinica M, Akgül B, Silling S, Mauch C, Zigrino P. Correlation of Merkel cell polyomavirus positivity with PDGFRα mutations and survivin expression in Merkel cell carcinoma. J Dermatol Sci 2015; 79:43-9. [DOI: 10.1016/j.jdermsci.2015.04.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Revised: 03/26/2015] [Accepted: 04/07/2015] [Indexed: 12/17/2022]
|
19
|
Abstract
Merkel cell carcinoma is a rare aggressive malignant neuroendocrine skin tumor, which can metastasize to lymph nodes early and often shows local recurrence. The prognosis depends on tumor size and disease stage. The majority of recurrences appear during the first 2 years after the primary diagnosis. The 5-year survival rate for primary tumor < 2 cm is 66-75 % and for primary tumors > 2 cm is 50-60 %. With lymph node metastases the 5-year survival rate is 42-52 %, while with distant metastases it drops to 17-12 %. Extensive staging inclusive sentinel lymph node biopsy is essential to assess the risk for distant metastasis and to allow the best recommendations for therapy. After surgical treatment with adequate safety margin, subsequent adjuvant radiation therapy of the tumor region and lymphatic draining basin is recommended to reduce the risk of local recurrence and lymphatic spread.
Collapse
Affiliation(s)
- F Kleffner
- Klinik und Poliklinik für Dermatologie und Venerologie, Hauttumorzentrum im CIO Köln Bonn, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland
| | | | | | | | | |
Collapse
|
20
|
Kleffner F, Schürholz J, Burckhardt S, Mauch C, Schlaak M. Erratum zu: Merkel-Zell-Karzinom. Hautarzt 2014. [DOI: 10.1007/s00105-014-3564-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol 2014; 25:1428-1436. [PMID: 24769640 DOI: 10.1093/annonc/mdu154] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. METHODS The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. RESULTS For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. CONCLUSIONS This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient. ClinicalTrials.gov Identifier: NCT01227889.
Collapse
Affiliation(s)
- J-J Grob
- Aix-Marseille University, APHM, Hôpital Timone, Marseille, France.
| | | | - S Martin-Algarra
- Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain
| | - L V Demidov
- Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | | | | | - P Haney
- GlaxoSmithKline, Collegeville, USA
| | - E Kämpgen
- Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany
| | | | - C Mauch
- Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany
| | - W H Miller
- Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada
| | - M Millward
- Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia
| | | | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | - V Chiarion-Sileni
- Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy
| | - S Swann
- GlaxoSmithKline, Collegeville, USA
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
22
|
Leufke C, Leykauf J, Krunic D, Jauch A, Holtgreve-Grez H, Böhm-Steuer B, Bröcker EB, Mauch C, Utikal J, Hartschuh W, Purdie KJ, Boukamp P. The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. Oncogene 2013; 33:3506-18. [DOI: 10.1038/onc.2013.323] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Revised: 05/14/2013] [Accepted: 06/17/2013] [Indexed: 12/12/2022]
|
23
|
Striegel AK, Nazzal R, Fabri M, Rietschel E, Dötsch J, Mauch C, Tantcheva-Poor I. Two cases of lupus vulgaris in childhood and review of the clinical challenges. Klin Padiatr 2013; 226:40-3. [PMID: 23599230 DOI: 10.1055/s-0033-1343412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Lupus vulgaris (LV) is the most common form of cutaneous tuberculosis (TB) in Europe, nevertheless the overall incidence is low. It constitutes about 1.5% of all extra-pulmonary cases worldwide. A slight raise in TB incidence rates among children was recently registered in Germany, which can be explained by the increased immigration. PATIENTS AND METHODS We present 2 cases of immigrated children who were diagnosed with Lupus vulagris, both clinically and histopathologically. Although the symptoms and the duration of the skin lesions were very different, both patients had a non-healing skin ulceration.In our cases cultures of the skin biopsy were positive for Mycobacterium tuberculosis and the lesions showed marked improvement in response to antituberculous treatment. In the first patient, it took 6 years between occurrence of skin lesions and final diagnosis. The second patient had an extracutaneous focus, namely abdominal TB. CONCLUSION We report our experience and emphasize on recent advances in the diagnosis and treatment of paediatric skin TB.
Collapse
Affiliation(s)
- A K Striegel
- Children's Hospital, University of Cologne, Germany
| | - R Nazzal
- Children's Hospital, University of Cologne, Germany
| | - M Fabri
- Dermatology and Venerology, University of Cologne, Germany
| | - E Rietschel
- Children's Hospital, University of Cologne, Germany
| | - J Dötsch
- Children's Hospital, University of Cologne, Germany
| | - C Mauch
- Dermatology and Venerology, University of Cologne, Germany
| | | |
Collapse
|
24
|
Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Br J Dermatol 2013; 168:708-16. [DOI: 10.1111/bjd.12140] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
25
|
Tantcheva-Poor I, Schuster A, Kornak U, Chelius K, Mauch C. Kongenitale autosomal rezessive Cutis laxa Typ II A Wrinkly-Skin-Syndrom. Klin Padiatr 2012; 224:322-3. [DOI: 10.1055/s-0032-1312677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol 2012; 4:56-60. [PMID: 22548037 PMCID: PMC3339687 DOI: 10.1159/000337433] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) of the α/β type is a rare subtype of non-Hodgkin's lymphoma of the skin. Although these tumors usually run an indolent course, disease-related morbidity is often severe. Clinical findings include subcutaneous tumors located on the extremities or trunk, often accompanied by systemic symptoms like fever or fatigue. Due to the low incidence of SPTL, no standardized therapy has been defined so far and there is currently no curative therapy available for this type of non-Hodgkin's lymphoma. By sharing our experience with bexarotene therapy, we present a safe and potentially improved treatment for patients with SPTL. In the case presented, bexarotene was able to induce remission even after recurrence of disease.
Collapse
Affiliation(s)
- X Zhang
- University Hospital of Cologne, Department of Dermatology, Skin Cancer Centre, Cologne, Germany
| | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- L Parise
- Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany
| | - J Kahle
- Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany
| | - M Schlaak
- Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany
| | - C Mauch
- Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany
| | - P Kurschat
- Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany.
| |
Collapse
|
28
|
Becker J, Gutzmer R, Mauch C. Medikamentöse Tumortherapie. Hautarzt 2011; 62:412-3. [DOI: 10.1007/s00105-010-2074-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
|
30
|
Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M, Hauschild A. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 2011; 22:1667-1674. [PMID: 21220519 DOI: 10.1093/annonc/mdq648] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The combination of sorafenib, a multikinase inhibitor, and pegylated interferon-α2b (Peg-IFN-α2b) could potentially lead to an improved antitumoral response. Previously, combinations of interferon and sorafenib have been used in renal cell cancer. PATIENTS AND METHODS Patients with stage IV metastatic melanoma and no previous systemic therapies apart from adjuvant immunotherapy received Peg-IFN-α2b 3 μg/kg once per week, and sorafenib 400-mg b.i.d. for a minimum of 8 weeks. The primary study end point was disease control rate (DCR). RESULTS Between February 2008 and February 2009, 55 patients were enrolled with a median age of 64 years (20-85). At 8 weeks, 2 patients (3.6%) had a partial response (PR) and 14 patients a stable disease (25.5%), for a DCR of 29.1% in the intention-to-treat (ITT) population. The median progression-free survival in the ITT population was 2.47 months (95% confidence interval 1.22-3.72 months). The toxicity of sorafenib and Peg-IFN-α2b combination was characterized by mainly hematological side-effects, including one treatment-related bleeding complication with a fatal outcome. Other grade 3/4 toxic effects were fatigue and flu-like symptoms. CONCLUSION The combination of sorafenib and Peg-IFN-α2b showed modest clinical activity and some serious side-effects including fatal bleeding complications.
Collapse
Affiliation(s)
- F Egberts
- Department of Dermatology, University of Kiel, Kiel
| | - R Gutzmer
- Department of Dermatology, Hannover Medical School, Hannover
| | - S Ugurel
- Department of Dermatology, University of Würzburg, Würzburg, Germany; Department of Dermatology, University of Graz, Graz, Austria
| | - J C Becker
- Department of Dermatology, University of Würzburg, Würzburg, Germany; Department of Dermatology, University of Graz, Graz, Austria
| | - U Trefzer
- Department of Dermatology, University of Berlin, Berlin
| | - A Degen
- Department of Dermatology, Hannover Medical School, Hannover
| | - F Schenck
- Department of Dermatology, Hannover Medical School, Hannover
| | - L Frey
- Department of Dermatology, University of Würzburg, Würzburg, Germany
| | - T Wilhelm
- Department of Dermatology, University of Berlin, Berlin
| | - J C Hassel
- Department of Dermatology, University of Heidelberg-Mannheim, Heidelberg
| | - D Schadendorf
- Department of Dermatology, University of Essen, Essen
| | - E Livingstone
- Department of Dermatology, University of Kiel, Kiel; Department of Dermatology, University of Essen, Essen
| | - C Mauch
- Department of Dermatology, University of Köln, Köln
| | - C Garbe
- Department of Dermatology, University of Tübingen, Tübingen
| | - C Berking
- Department of Dermatology, University of Munich, Munich
| | - K Rass
- Department of Dermatology, University of Homburg/Saar, Homburg/Saar
| | - P Mohr
- Dermatological Center, Buxtehude, Buxtehude, Germany
| | - K C Kaehler
- Department of Dermatology, University of Kiel, Kiel
| | | | - A Hauschild
- Department of Dermatology, University of Kiel, Kiel.
| |
Collapse
|
31
|
Akgul B, Bauer B, Zigrino P, Storey A, Mauch C, Pfister H. Upregulation of lipocalin-2 in human papillomavirus-positive keratinocytes and cutaneous squamous cell carcinomas. J Gen Virol 2010; 92:395-401. [DOI: 10.1099/vir.0.025064-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
32
|
Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, Schadendorf D. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010; 103:820-6. [PMID: 20736948 PMCID: PMC2966614 DOI: 10.1038/sj.bjc.6605796] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma. In glioblastoma, promoter methylation of the counteracting DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) correlates with survival of patients exposed to TMZ in combination with radiotherapy. For melanoma, data are limited and controversial. Methods: Biopsy samples from 122 patients with metastatic melanoma being treated with TMZ in two multicenter studies of the Dermatologic Cooperative Oncology Group were investigated for MGMT promoter methylation. We used the COBRA (combined bisulphite restriction analysis) technique to determine aberrant methylation of CpG islands in small amounts of genomic DNA isolated from paraffin-embedded tissue sections. To detect aberrant methylation, bisulphite-treated DNA was amplified by PCR, enzyme restricted, and visualised by gel electrophoresis. Results: Correlation with clinical data from 117 evaluable patients in a best-response evaluation indicated no statistically significant association between MGMT promoter methylation status and response. A methylated MGMT promoter was observed in 34.8% of responders and 23.4% of non-responders (P=0.29). In addition, no survival advantage for patients with a methylated MGMT promoter was detectable (P=0.79). Interestingly, we found a significant correlation between MGMT methylation and tolerance of therapy. Patients with a methylated MGMT promoter had more severe adverse events, requiring more TMZ dose reductions or discontinuations (P=0.007; OR 2.7 (95% CI: 1.32–5.7)). Analysis of MGMT promoter methylation comparing primaries and different metastases over the clinical course revealed no statistical difference (P=0.49). Conclusions: In advanced melanoma MGMT promoter, methylation correlates with tolerance of therapy, but not with clinical outcome.
Collapse
Affiliation(s)
- J C Hassel
- Skin Cancer Unit, German Cancer Research Center, University Hospital Mannheim, Mannheim, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hauschild A, Gutzmer R, Ugurel S, Trefzer U, Egberts F, Hassel J, Schadendorf D, Mauch C, Garbe C, Weichenthal M. Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Eberle J, Spangler B, Becker JC, Heinemann SH, Klein CA, Kunz M, Kuphal S, Langer P, Mauch C, Meierjohann S, Paschen A, Schadendorf D, Schartl M, Schittek B, Schönherr R, Tüting T, Zigrino P, Bosserhoff AK. Multicentre study on standardisation of melanoma cell culture--an initiative of the German Melanoma Research Network. Pigment Cell Melanoma Res 2010; 23:296-8. [PMID: 20137059 DOI: 10.1111/j.1755-148x.2010.00684.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Ugurel S, Neuber K, Pfoehler C, Mauch C, Ulrich J, Schadendorf D. Pegylated liposomal doxorubicin plus paclitaxel as an individualized chemosensitivity-directed treatment in advanced metastatic melanoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8551 Background: Melanoma is a cutaneous neoplasm known for its high agressiveness and its poor prognosis once metastasized. Dacarbacine chemotherapy is actually considered standard first-line treatment of metastatic melanoma, with reported response rates of 6–7%. Due to this unsatisfactory situation, a number of non-standard anti-cancer drugs have been tested for improved efficacy. The present study was aimed to test doxorubicin plus paclitaxel in metastatic melanoma patients based on in-vitro chemosensitivity of this drug combination in fresh tumor samples. Methods: The primary study endpoint was objective response, secondary endpoints were safety and overall survival. Patients with histologically confirmed metastatic melanoma (AJCC stage IV), measurable tumor parameters, and an in-vitro chemosensitivity to doxorubicin plus paclitaxel which is superior to other test drugs determined by an ATP-based luminescence viability assay, were eligible. Patients received paclitaxel 175 mg/m2 i.v. followed by pegylated liposomal doxorubicin 30 mg/m2 i.v. at d1 every 28 days. Tumor assessment was performed every 8 weeks and evaluated according to RECIST. Treatment was continued at a tumor response of stable disease (SD) or better, and stopped in case of disease progression (PD) or intolerable side effects. Results: Out of 14 patients enrolled into this study, 12 received study treatment as first-line, and two as second-line therapy. Objective response was 14.3% (1 CR, 1 PR); progression arrest was 28.6% (1 CR, 1 PR, 2 SD). Median overall survival was 9.7 months. Common slight to moderate side effects were myelosuppression and neurotoxicity. Severe toxicities (CTC grade 3/4) were experienced by three patients (21.4%), with two of them presenting severe myelosuppression, and one experiencing myocardial infarction. Conclusions: Pegylated liposomal doxorubicin combined with paclitaxel shows significant efficacy in advanced metastatic melanoma if applied in an individualized, sensitivity- directed regimen. The observed side effects were comparable to other combination chemotherapies. This treatment regimen needs further evaluation in larger clinical trials containing standard therapy control groups. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Ugurel
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| | - K. Neuber
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| | - C. Pfoehler
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| | - C. Mauch
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| | - J. Ulrich
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| | - D. Schadendorf
- German Cancer Research Center, Mannheim, Germany; University of Hamburg, Hamburg, Germany; The Saarland University Hospital, Homburg/Saar, Germany; University of Cologne, Cologne, Germany; University of Magdeburg, Magdeburg, Germany
| |
Collapse
|
36
|
Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 2007; 156:653-8. [PMID: 17263813 DOI: 10.1111/j.1365-2133.2006.07724.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Increased serum levels of angiogenesis-related factors such as endostatin, vascular endothelial cell growth factor (VEGF) or basic fibroblast growth factor (bFGF) have been demonstrated for a variety of solid and nonsolid tumours. Therefore, these factors have been suggested as diagnostic and in some studies as prognostic tumour markers. OBJECTIVES The purpose of the present study was to investigate a possible correlation of endostatin, VEGF or bFGF serum levels with disease progression in melanoma. Especially, we compared these factors to the established melanoma marker S-100 B, which increases in advanced disease but often fails to indicate early metastatic spread to regional lymph nodes. PATIENTS AND METHODS Sera from 197 melanoma patients and 35 healthy controls were measured by enzyme-linked immunosorbent assay; 72 patients had primary tumours (American Joint Committee on Cancer stages I and II), 55 had regional lymph node metastasis (stage III) and 70 patients had distant organ metastasis (stage IV). RESULTS Endostatin, VEGF and bFGF serum levels were significantly elevated in stage IV disease, compared with the control group. In stage III, endostatin and bFGF, but not VEGF or S-100 B, were significantly increased. However, follow-up of this patient group did not show a correlation with the future clinical course including time until progression or overall survival, arguing against a role of endostatin, VEGF or bFGF as prognostic markers. CONCLUSIONS These data indicate that endostatin or bFGF might be useful as diagnostic markers for the early detection of locoregional metastasis.
Collapse
Affiliation(s)
- P Kurschat
- Department of Dermatology and Center for Molecular Medicine CMMC, University of Cologne, Josef-Stelzmann-Str. 9, 50924 Cologne, Germany
| | | | | | | | | |
Collapse
|
37
|
Terheyden P, Kortüm AK, Schulze HJ, Durani B, Remling R, Mauch C, Junghans V, Schadendorf D, Beiteke U, Jünger M, Becker JC, Bröcker EB. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol 2007; 133:437-44. [PMID: 17334785 DOI: 10.1007/s00432-006-0182-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2006] [Accepted: 12/04/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE To scrutinize published data from small mono-centric studies and case reports which implicated high response rates and promising survival times for a combination therapy consisting of epifocal dinitrochlorobenzene (DNCB) and dacarbazine (DTIC) for metastasized melanoma. This therapy merges the effects of an allergic contact dermatitis elicited at the site of a cutaneous metastasis, and systemic chemotherapy. METHODS We performed a retrospective survey with nine German centers and evaluated 72 patients treated from 1993 to 2005. RESULTS The objective response rate in stage III melanoma (n = 39) was 62%. In contrast, only 9% objective responses were observed in 33 stage IV patients. Interestingly, more than half of patients with objective remissions remained progression-free for more than 1 year irrespective of the stage of disease. CONCLUSIONS Epifocal DNCB combined with DTIC is effective in patients with regionally metastasized melanoma not amenable to surgery or isolated limb perfusion, whereas in stage IV disease in spite of few durable remissions the addition of DNCB does not improve the therapeutic efficacy of DTIC.
Collapse
Affiliation(s)
- P Terheyden
- Department of Dermatology, University of Würzburg, Josef-Schneider Str. 2, 97080 Würzburg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Keratinocyte growth factor (KGF) is an important regulator of epidermal homeostasis and repair. Therefore, the identification of KGF target genes in keratinocytes should contribute to our understanding of the molecular mechanisms underlying these processes. In a search for KGF-regulated genes, we identified the gene encoding the nucleoside diphosphate kinase NM23-H1. Apart from a housekeeping function, NM23 proteins are involved in the regulation of many cellular processes as well as in tumor metastasis, but their functions in epidermal homeostasis and repair are largely unknown. Here, we show a high expression of NM23-H1 and NM23-H2 in the KGF-responsive keratinocytes of the hyperproliferative epidermis of mouse skin wounds and of patients suffering from the skin disease psoriasis. To determine if this overexpression is functionally important, we generated HaCaT keratinocyte cell lines overexpressing NM23-H1 and/or -H2. Whereas the enhanced levels of NM23 did not affect cell proliferation in monoculture, NM23-H2 and double transfectants but not NM23-H1 transfectants formed a strongly hyperthickened epithelium in three-dimensional organotypic cultures. The abnormal epithelial morphology resulted from enhanced proliferation, reduced apoptosis and alterations in the differentiation pattern. These findings suggest that epidermal homeostasis depends on a tight regulation of the levels of NM23 isoforms.
Collapse
Affiliation(s)
- S Braun
- Institute of Cell Biology, ETH Zurich, Hönggerberg, Zurich, Switzerland
| | | | | | | |
Collapse
|
39
|
Billion K, Ibrahim H, Mauch C, Niessen CM. Increased Soluble E-Cadherin in Melanoma Patients. Skin Pharmacol Physiol 2006; 19:65-70. [PMID: 16685144 DOI: 10.1159/000091972] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Accepted: 01/27/2006] [Indexed: 11/19/2022]
Abstract
Cadherin switching is thought to contribute to melanoma progression. E-cadherin expression is downregulated, facilitating the release of contacts with keratinocytes, while N-cadherin expression is increased, potentially contributing to more migration. Proteolytic cleavage of the cadherin extracellular domain, a process called ectodomain shedding, is one way to decrease cadherin cell surface expression. In addition, the released ectodomain could actively contribute to a more invasive phenotype. To examine if melanoma progression correlates with increased cadherin ectodomain shedding, we tested the presence of N- and E-cadherin extracellular domains in different melanoma cell lines and the presence of E-cadherin in sera of patients. Shedding occurs and is regulated in several melanoma cell lines expressing these cadherins. No correlation could be found between cadherin shedding and invasive capacity of the cell lines. However, we did find a significant increase in serum E-cadherin levels of melanoma patients with advanced disease correlating with increased S100 tumor marker values, suggesting that increased cadherin shedding may contribute to melanoma progression.
Collapse
Affiliation(s)
- K Billion
- Center for Molecular Medicine, University of Cologne, Germany
| | | | | | | |
Collapse
|
40
|
Hummerich L, Müller R, Hess J, Kokocinski F, Hahn M, Fürstenberger G, Mauch C, Lichter P, Angel P. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 2006; 25:111-21. [PMID: 16247483 DOI: 10.1038/sj.onc.1209016] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Chemically induced mouse skin carcinogenesis represents the most extensively utilized animal model to unravel the multistage nature of tumour development and to design novel therapeutic concepts of human epithelial neoplasia. We combined this tumour model with comprehensive gene expression analysis and could identify a large set of novel tumour-associated genes that have not been associated with epithelial skin cancer development yet. Expression data of selected genes were confirmed by semiquantitative and quantitative RT-PCR as well as in situ hybridization and immunofluorescence analysis on mouse tumour sections. Enhanced expression of genes identified in our screen was also demonstrated in mouse keratinocyte cell lines that form tumours in vivo. Self-organizing map clustering was performed to identify different kinetics of gene expression and coregulation during skin cancer progression. Detailed analysis of differential expressed genes according to their functional annotation confirmed the involvement of several biological processes, such as regulation of cell cycle, apoptosis, extracellular proteolysis and cell adhesion, during skin malignancy. Finally, we detected high transcript levels of ANXA1, LCN2 and S100A8 as well as reduced levels for NDR2 protein in human skin tumour specimens demonstrating that tumour-associated genes identified in the chemically induced tumour model might be of great relevance for the understanding of human epithelial malignancies as well.
Collapse
Affiliation(s)
- L Hummerich
- Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
The development and progression of tumors result from the concerted activity not only of tumor cells with neighboring cells e.g., fibroblasts and inflammatory cells. Host-tumor interactions are considered critical in tumor invasion and metastasis. In vitro studies as well as established in vivo models have analysed the reciprocal effects of tumor-host interactions for the tumor invasion process. These studies have shown that modifications in the extracellular matrix composition surrounding the tumors as well as alterations in the expression of tumor cell receptors or in the expression of growth factors/cytokines and proteases, are critical regulators of a developing tumor. We shortly review the most important and well characterized mechanisms involved in the progression of tumor cells through tissues, especially those participating in cellular communication, cell adhesion, and proteolysis.
Collapse
Affiliation(s)
- P Zigrino
- Department of Dermatology and Center for Molecular Medicine (CMMC), University of Cologne, Joseph-Stelzmann strasse, 50931 Cologne, Germany
| | | | | |
Collapse
|
42
|
Affiliation(s)
- C Mauch
- Bilkei Consulting, Raubbühlstrasse 4, Dübendorf CH-8600, Switzerland
| | | |
Collapse
|
43
|
Mauch C, Bilkei G. The influence of prepartal bacteriuria on the reproductive performance of the sow. Dtsch Tierarztl Wochenschr 2004; 111:166-9. [PMID: 15171603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
UNLABELLED In a Slowakian indoor pig production unit, with high prevalence of vaginal-vulval discharges, the sows were subjected one day prefarrowing to urine analysis. Sows suffering urinary tract infection (UTI) were assigned to an UTI group (group 1, n = 384), the remaining sows were classified as free of UTI and were assigned to group 2 (n = 1099). Total born litter size, liveborn litter size, weaning litter size and the occurrence of periparturient diseases, reasons for sow cullings at weaning, subsequent weaning to estrus intervals, conceptions- and farrowing rate, next total born- and lifeborn litter size and the occurrence of periparturient diseases were evaluated. UTI having sows had smaller (p < 0.05) total born litter size (11.71 +/- 1.11) when compared to the healthy animals (12.97 +/- 1.25). Liveborn litter size was significantly (p < 0.01) lower in group 1 (10.21 +/- 0.81 vs. group 2: 11.31 +/- 1.21). The occurrence of periparturient diseases revealed highly significant (p < 0.001) differences between the groups (group one 26.24% vs. group two 4.64%). Weaning litter size showed significant (p < 0.05) differences between group 1 (9.21 +/- 1.02) and 2 (10.11 +/- 0.37). More (p < 0.05) sows were culled post-weaning in the UTI group, compared to the healthy animals. Causes of post-weaning cullings differed between the groups: all sows of the group one had the pathological signs of swine urogenital disease at culling, while the majority of sows of the group 2 were culled due to locomotor problems and chronic mastitis. Subsequent weaning to estrus intervals, conceptions-, and farrowing rate and next total born litter size differed significantly (p < 0.05) between the groups, next lifeborn litter size (p < 0.01) and the occurrence of periparturient diseases (p < 0.001) were high significantly better in the healthy than in the UTI suffering group of sows. IMPLICATIONS antepartal UTI might be the sign of swine urogenital disease and might negatively influence the sows reproductive performance.
Collapse
Affiliation(s)
- C Mauch
- Bilkei Consulting, Dübendorf, Switzerland
| | | |
Collapse
|
44
|
Mauch C, Bilkei G. Strategic application of oregano feed supplements reduces sow mortality and improves reproductive performance - a case study. J Vet Pharmacol Ther 2004; 27:61-3. [PMID: 14995969 DOI: 10.1046/j.0140-7783.2003.00531.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- C Mauch
- Bilkei Consulting, Raubbühlstrasse 4, CH-8600 Dübendorf, Switzerland
| | | |
Collapse
|
45
|
Herrmann G, Groth W, Krieg T, Mauch C. Komplette Remission eines lokoregionär metastasierten Merkelzell-Karzinoms des Kopfes nach fokaler Behandlung mit Dinitrochlorbenzol. Akt Dermatol 2003. [DOI: 10.1055/s-2003-822256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Krug B, Stützer H, Wolters U, Mauch C, Staib P, Töx U, Steffen HM, Warm M, Ghafur S, Araba F, Beuckelmann D, König DP, Zähringer M, Palm S, Von Pritzbuer E, Schrappe M. [Development of ultrasonography in a radiological university department from 1994 to 2001]. ROFO-FORTSCHR RONTG 2002; 174:767-75. [PMID: 12063609 DOI: 10.1055/s-2002-32225] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
BACKGROUND In 1994, 5 % of a total of 25 718 examinations and 7 % of all 4630 B-mode sonograms performed in the Radiology Department, University of Cologne was classified as not indicated. In light of these results, the health care policy guidelines for sonographic indications have been amended. PURPOSE The aim of this study was to establish the current rate of non-indicated sonographic examinations performed in routine diagnostics by radiology departments at university hospitals, to determine the reasons for such over-diagnosis and identify which regulatory mechanisms can be implemented to prevent his. METHOD We counted the number of 1) B-mode and 2) color-flow Doppler ultrasound imaging procedures carried out in patients who had had no change in symptoms within the previous 4 weeks or who were scheduled without reference to an existing sonogram (double examinations). 3) The reasons for over-diagnosis were analyzed. 4) The 1994 survey was repeated in 2000 with an identical protocol and 5) additionally, a modified survey of the diagnostic questions was conducted. RESULTS 1) Out of 4,119 patients presenting for the first time to receive a B-mode sonogram, 443 prior sonograms (11 %), 305 CT scans (7 %) and 57 MRI scans (1 %) were documented. 2) Double sonograms were carried out in 6 % of the 1,118 patients presenting for the first time for color-flow Doppler ultrasounds and in 16 % of the 651 patients assigned to receive catheter angiographies with arterial color-flow Doppler. 2) 41 out of 55 (75 %) prior sonograms from non-university settings stated by 94 surgery patients were listed in the medical records. 36 out of 43 (84 %) prior sonograms from the university hospital were repeated in the same patients despite the fact that the medical report with the findings was available. None of the 48 sonograms indicated to confirm a plausible finding yielded any information that was additionally relevant to therapy. 4) In the period April - June, 2000, 12 % of all 15,921 tests and interventions, 26 % of 3,569 B-mode sonograms and 58 % of 1,033 abdominal sonograms performed in adults were classified as having not been indicated. 5) Staging and follow-up were stated as the most common reasons that a sonography was carried out in 46 % of the 1,017 adults who were given B-mode sonograms conducted from Jan - Mar, 2000 and comprised 62 % of the 410 sonograms classified as not or probably not medically indicated. CONCLUSION The results showed that a multidisciplinary consensus was required to establish the diagnostic value of sonographic procedures. Therefore, this research group drafted a hospital-internal interdisciplinary guideline for "abdominal transcutaneous B-mode sonography in oncological questions".
Collapse
Affiliation(s)
- B Krug
- Institut und Poliklinik für Radiologische Diagnostik der Universität Köln, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Hunzelmann N, Kurschat P, Hani N, Jarisch A, Mauch C. Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in children. Br J Dermatol 2002; 146:536-7. [PMID: 11952568 DOI: 10.1046/j.1365-2133.2002.465710.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
48
|
Werner S, Beer HD, Mauch C, Lüscher B, Werner S. The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis. Oncogene 2001; 20:7494-504. [PMID: 11709721 DOI: 10.1038/sj.onc.1204937] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2001] [Revised: 08/23/2001] [Accepted: 08/28/2001] [Indexed: 11/08/2022]
Abstract
Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, affects keratinocyte proliferation and differentiation in vitro and in vivo. However, little is known about the mechanisms of activin action in keratinocytes, and its target genes have not been identified. In this study, we demonstrate that activin A and TGF-beta1 directly induce the expression and activity of Mad1, an antagonist of the c-Myc transcription factor, in the human HaCaT keratinocyte cell line. Expression and activity of Mad1 was strongly induced by both factors in keratinocytes, although the intensity of induction was different for activin A and TGF-beta1. To determine a possible role of activin and TGF-beta in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair when high levels of these factors are present. Expression of mad1 mRNA and protein, but not of other mad genes, increased significantly after skin injury, particularly in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium. Elevated levels of mad1 mRNA were also detected in the hyperthickened epidermis of psoriatic patients. Since Mad1 regulates proliferation and/or differentiation of various cell types, our results suggest that this transcription factor mediates at least in the part the anti-mitotic and/or differentiation-inducing activities of TGF-beta and activin in keratinocytes.
Collapse
Affiliation(s)
- S Werner
- Institute of Cell Biology, ETH Zürich Hönggerberg, CH-8093 Zürich, Switzerland
| | | | | | | | | |
Collapse
|
49
|
Mauch C, Grimm C, Meckel S, Wands JR, Blum HE, Roggendorf M, Geissler M. Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice. Vaccine 2001; 20:170-80. [PMID: 11567762 DOI: 10.1016/s0264-410x(01)00252-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The cellular immune response is a crucial defense mechanism against hepatotropic viruses and in chronic viral hepatitis prevention. Moreover, hepatitis delta virus (HDV) immunogenicity may be an important component in the development of prophylactic and therapeutic vaccines. Therefore, we evaluated the immunogenicity of the small (HDAg) or large delta antigen (LHDAg) to be used as a DNA-based vaccine. We immunized different mouse haplotypes, determined cellular immune responses, and tested protection of animals against tumor formation using syngeneic tumor cells stably expressing the delta antigens. Both LHDAg and HDAg primed CD4+ and CD8+ T cell immunity against both forms of delta antigens. CD8+ T cell frequencies were about 1% and antigen-specific CD8+ T cells remained detectable directly ex vivo for at least 35 days post-injection. No anti-delta antibody responses could be detected despite multiple detection systems and varied immunization approaches. We observed protection against syngeneic tumor formation and growth in mice immunized with DNA plasmids encoding secreted or intracellular forms of HDAg and LHDAg but not with recombinant HDAg establishing the generation of significant cellular immunity in vivo. Both CD4+ and CD8+ T cells were required for antitumoral activity as determined by in vivo T cell depletion experiments. The results indicate that DNA-based immunization with genes encoding LHDAg and HDAg induces strong T cell responses and, therefore, is an attractive approach for the construction of therapeutic and prophylactic T cell vaccines against HDV.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/analysis
- CD4-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/immunology
- Cell Line
- Cytotoxicity, Immunologic
- Defective Viruses/immunology
- Drug Evaluation, Preclinical
- Female
- Genetic Vectors/administration & dosage
- Genetic Vectors/genetics
- Haplotypes
- Hepatitis Antigens/immunology
- Hepatitis Delta Virus/immunology
- Hepatitis delta Antigens
- Immunity, Cellular
- Interferon-gamma/biosynthesis
- Lymphocyte Activation
- Mast-Cell Sarcoma/immunology
- Mast-Cell Sarcoma/pathology
- Mast-Cell Sarcoma/prevention & control
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Muscle, Skeletal/cytology
- Neoplasm Transplantation
- Recombinant Proteins/immunology
- T-Lymphocytes, Cytotoxic/immunology
- Transfection
- Tumor Cells, Cultured/transplantation
- Vaccines, DNA/immunology
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- C Mauch
- Department of Medicine II, University Hospital Freiburg, Hugstetter Strasse 55, D-79106, Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
50
|
Jöckel A, Kopner RM, Casper C, Mauch C, Scharffetter-Kochanek K, Hunzelmann N. [Persistent vulvar edema]. Hautarzt 2001; 52:743-5. [PMID: 11544949 DOI: 10.1007/s001050170094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Jöckel
- Klinik und Poliklinik für Dermatologie und Venerologie der Universität zu Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln
| | | | | | | | | | | |
Collapse
|